Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

John van der Valk Appointed MD of UBM Live Amsterdam

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Valk responsible for overseeing the company’s flagship brand CPhI.

UBM Live has announced the appointment of John van der Valk as the new Managing Director of the UBM Live Amsterdam business.

His responsibilities will include the management of the pharma portfolio including the Company’s flagship brand CPhI Worldwide, which continues to evolve as the leading pharmaceutical event globally.

As part of his new role, John is focusing on the integration of digital media within the live events portfolio. One example is the CPhI Online directory, which provides pharmaceutical buyer’s access to the CPhI database of the industry’s foremost suppliers, including a search function for individual services and products.

The ultimate goal is to make it easier for exhibitors to meet with international pharmaceutical companies, stay informed about the latest industry trends and remain ahead of a constantly changing pharmaceutical market.

John has over 15 years' experience within the events and media business, and comes to UBM Live from VNU. He has extensive knowledge of large-scale trade and consumer shows, digital marketing services, partner relationships and product development.

"I am delighted that John has joined the UBM Live team. John's experience and expertise is invaluable to his leadership of the Food and Pharma portfolios as we continue to focus on our customer's needs, and the deliverance of outstanding customer experience," stated Simon Foster, CEO of UBM Live.

Foster continued, "John's contributions to the UBM Live Board, and to our global collaborations for growth and development of the business, play a significant role."

Commenting on his appointment, John van der Valk remarked, "It is a really exciting time to be joining UBM Live as we build a global portfolio of industry leading pharma events. Working alongside Chris Kilbee, together we look forward to helping grow the pharma portfolio so that CPhI Worldwide and sister events continue to drive growth, partnerships and business across the pharma industry. Our aims for 2014 are to launch our events in new markets and to expand the scope of content we provide so that we can help industry stay in touch year round.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CPhI Korea Opens as South Korea Emerges as Global Leader in Biosimilar Trials
Government’s R&D strategy and “Pharma 2020 Vision” to see country as drug development leader.
Monday, July 27, 2015
CPhI Announces USA Market Report at InformEx
Country report to contain contrasting insights into the American pharma economy from European and domestic perspectives.
Wednesday, January 22, 2014
Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
Kilbee responsible for driving the portfolio globally including increased emphasis on digital and content.
Monday, January 13, 2014
CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
Growth in the World’s second largest pharma region facilitated by innovation and loosened regulatory guidelines.
Monday, December 30, 2013
Rise of Generics and Patent Expirations Sees CPhI and P-MEC India 2013 Expand
Free online registration to attend CPhI and P-MEC India is now closed.
Tuesday, December 03, 2013
CPhI Worldwide 2013 Hosted More Than 34,000 Global Pharma Professionals
This year sees strong growth in APIs, biopharma, natural extracts, packaging and finished dosage with a highlight on innovation.
Tuesday, November 26, 2013
India Sets Ambitious Pharma Export Growth Targets
Indian generics exports growing at 24% per annum.
Monday, October 21, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!